Key figures

Boulevard Patience et Beaujonc 3
4000 Liège
+32 476 53 65 94

ABSCINT focuses on the development of radiolabelled single domain antibodies for whole body molecular imaging applications, to be used for the diagnosis of disease, for molecular characterisation of a disease, for monitoring treatment response and for detection of disease recurrence. The company has two clinical stage products: one in oncology and one in cardiovascular disease.

Activities and description

The unique performance of ABSCINT’s tracers relies on the synergistic combination of single-domain antibodies and short half-life radionuclides, such as Gallium-68. This combination offers numerous advantages, such has high specificity, low immunogenicity, high stability, rapid, homogeneous and deep tissue penetration, rapid clearance of unbound fraction, low irradiation burden, access to on-demand radiolabelling with 68Ga generators.

Targeted market

Ongoing projects/partnerships/collaborations

Background: The human epidermal growth factor receptor 2 (HER2) is a growth-promoting protein on the outside of all breast cells. Breast cancer cells with higher than normal levels of HER2 are called HER2-low or positive. These cancers tend to grow and spread faster than other breast cancers. However, they are also much more likely to respond to treatment with drugs that target the HER2 protein. Until end of 2022, only HER2-positive breast (and gastric) cancer patients received HER2 targeted treatment. All other patients were considered as being HER2-negative. Recently, HER2 classification was refined into three categories: HER2-positive, HER2-low and HER2-zero
Objective of ABSCINT-HER2
Tumor characterization
Early diagnosis of patients suffering from HER2 cancer, including HER2-(ultra)low
Mapping of HER2 heterogeneity
Follow-up of patients diagnosed with HER2 metastases

Background: Cardiac sarcoidosis is a life-threatening disease that causes cells to clump together into granulomas that disrupt heart function, with the risk of leading to sudden cardiac death. Current diagnosis methods are uncomfortable, non-specific and complex. More than 100,000 patients are diagnosed with sarcoidosis per year, from which over 25,000 patients have cardiac sarcoidosis. Sarcoidosis often affects young people.
Objective of ABSCINT-206
Follow-up of patients diagnosed with sarcoidosis
Early and correct diagnosis of cardiac sarcoidosis